conjunctivochalasis

con·junc·ti·vo·chal·a·sis

(kon-junk'ti-vō-kal'ă-sis),
Condition in which redundant bulbar conjunctiva billows over the eyelid margin or covers the lower punctum.
[conjunctiva + G. chalasis, a loosening]
Farlex Partner Medical Dictionary © Farlex 2012

con·junc·ti·vo·chal·a·sis

(kŏn-jŭngk-tī'vō-kă-lă'sis)
Condition in which redundant bulbar conjunctiva billows over the eyelid margin or covers the lower punctum
[conjunctiva + G. chalasis, a loosening]
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
Wize Pharma has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis and Sjgren's Syndrome.
Surgical treatment for conjunctivochalasis [right arrow] Aqueous supplementation 4.2.
HPGC Medical Co has been engaged for the distribution of the drug formula LO2A for the treatment of dry eye syndrome (DES) and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjogren's syndrome (Sjogren's) in China.
Yu, "Analysis of tear mucin and goblet cells in patients with conjunctivochalasis," Spektrum der Augenheilkunde, vol.
The inclusion criteria: 1.- Without lacrimation, dry eye and other ocular discomforts; 2.- The tear secretion was normal; 3.- The slit lamp examination exhibited no abnormality of punctal shape and position, conjunctivochalasis, hypertrophy of lacrimal caruncle and anterior segment inflammation, etc.; 4.- Without abnormality of eyelid medial canthus and eyelid- related diseases; 5.- Without previous surgery and trauma history in the ocular region, head and face.
* Conjunctivochalasis (CCH) (see Figure 2, page 47) occurs when the conjunctiva loses its adherence to the underlying tissue, forming multiple folds.
It has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis and Sjogren's syndrome.
Conjunctivochalasis (CCh) was first described at 1942 by Hughes (1) as redundant, loose, nonedematous inferior bulbar conjunctiva interposed between the globe and the lower eyelid.
These signs include rounding of lid margins, notching of lid margins, vascularity of lid margins, lashes abnormity, hyperkeratinization, hyperemia of lid margins, main duct number (central 1 cm), plugging of orifices, scarred obliteration of orifices, main duct dropout, properties of the secretion, tear film breakup time (BUT), tear film fragment, tear film foam, upper tear meniscus height, lower tear meniscus height, conjunctival congestion, conjunctivochalasis, and corneal fluorescein staining.
A progressive impairment of this lymphatic system is also thought to be responsible for the development of conjunctivochalasis, (5) perhaps better known by the acronym lid-parallel-conjunctival-folds or LIPCOF.
The other tissue change to be considered in the ageing eye is the presence of lid parallel conjunctival folds (LIPCOF) or conjunctivochalasis (a baggy conjunctiva with folds that may rest on the lower eyelid) (2).